Skip to main content
Erschienen in: The International Journal of Cardiovascular Imaging 9/2023

26.05.2023 | Original Paper

The role of left ventricular hypertrophy measured by echocardiography in screening patients with ischaemia with non-obstructive coronary arteries: a cross-sectional study

verfasst von: Hao Yang, Hua Teng, Peng Luo, Ruqian Fu, Xiaoting Wang, Guang Qin, Min Gao, Jianli Ren

Erschienen in: The International Journal of Cardiovascular Imaging | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Many patients with ischaemia with non-obstructive coronary arteries (INOCA) have a poor prognosis. This study aims to explore the diagnostic value of left ventricular hypertrophy (LVH)-related ultrasound parameters in INOCA patients. The study group consisted of 258 patients with INOCA in this retrospective cross-sectional study, and these patients were free of obstructive coronary artery disease, previous revascularization, atrial fibrillation, ejection fraction < 50%, major distortions of left ventricular geometry, suspected non-ischaemic causes. Control individuals were matched 1:1 with study group according to age, sex, cardiovascular risk factors, and time of hospital stay. According to left ventricular mass index (LVMI) and relative wall thickness, left ventricular geometry was composed of concentric hypertrophy, eccentric hypertrophy, concentric remodeling and normal geometry. LVH-related parameters, left ventricular geometry, demographic characteristics, laboratory parameters and other echocardiographic indicators were compared between the two groups. Subgroup analysis was performed based on sex. LVMI in the study group was higher than that in the control group (86.86 ± 18.83 g/m2 vs 82.25 ± 14.29 g/m2, P = 0.008). The ratio of LVH was higher in the study group (20.16% vs 10.85%, P = 0.006). After subgroup analysis based on sex, LVMI differences (85.77 ± 18.30 g/m2 vs 81.59 ± 14.64 g/m2, P = 0.014) and the ratio of LVH differences (25.00% vs 14.77%, P = 0.027) still existed in females between the two groups. There was no difference in the constituent ratio of left ventricular geometry between the two groups (P = 0.157). Sex-based subgroup analysis showed no difference in the constituent ratio of left ventricular geometry between the two groups in females (P = 0.242). The degree of LVH in the study group was higher than that in the control group, suggesting that LVH may play an important role in the occurrence and development of INOCA. Moreover, LVH-related ultrasound parameters may be of higher diagnostic value for female INOCA patients than for male INOCA patients.
Literatur
2.
Zurück zum Zitat Bairey Merz CN, Pepine CJ, Walsh MN et al (2017) Ischemia and No Obstructive Coronary Artery Disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation 135(11):1075–1092CrossRefPubMed Bairey Merz CN, Pepine CJ, Walsh MN et al (2017) Ischemia and No Obstructive Coronary Artery Disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation 135(11):1075–1092CrossRefPubMed
3.
Zurück zum Zitat Beltrame JF, Tavella R, Jones D et al (2021) Management of ischaemia with non-obstructive coronary arteries (INOCA). BMJ 375:e060602CrossRefPubMed Beltrame JF, Tavella R, Jones D et al (2021) Management of ischaemia with non-obstructive coronary arteries (INOCA). BMJ 375:e060602CrossRefPubMed
4.
Zurück zum Zitat Schroder J, Prescott E (2021) Doppler echocardiography assessment of coronary microvascular function in patients with angina and no obstructive coronary artery disease. Front Cardiovasc Med 8:723542CrossRefPubMedPubMedCentral Schroder J, Prescott E (2021) Doppler echocardiography assessment of coronary microvascular function in patients with angina and no obstructive coronary artery disease. Front Cardiovasc Med 8:723542CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Schroder J, Michelsen MM, Mygind ND et al (2021) Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study. Eur Heart J 42(3):228–239CrossRefPubMed Schroder J, Michelsen MM, Mygind ND et al (2021) Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study. Eur Heart J 42(3):228–239CrossRefPubMed
6.
Zurück zum Zitat Pries AR, Reglin B (2017) Coronary microcirculatory pathophysiology: can we afford it to remain a black box? Eur Heart J 38(7):478–488PubMed Pries AR, Reglin B (2017) Coronary microcirculatory pathophysiology: can we afford it to remain a black box? Eur Heart J 38(7):478–488PubMed
7.
Zurück zum Zitat Pries AR, Habazettl H, Ambrosio G et al (2008) A review of methods for assessment of coronary microvascular disease in both clinical and experimental settings. Cardiovasc Res 80(2):165–174CrossRefPubMed Pries AR, Habazettl H, Ambrosio G et al (2008) A review of methods for assessment of coronary microvascular disease in both clinical and experimental settings. Cardiovasc Res 80(2):165–174CrossRefPubMed
8.
Zurück zum Zitat Shimokawa H, Suda A, Takahashi J et al (2021) Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur Heart J 42(44):4592–4600CrossRefPubMedPubMedCentral Shimokawa H, Suda A, Takahashi J et al (2021) Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur Heart J 42(44):4592–4600CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ford TJ, Rocchiccioli P, Good R et al (2018) Systemic microvascular dysfunction in microvascular and vasospastic angina. Eur Heart J 39(46):4086–4097CrossRefPubMedPubMedCentral Ford TJ, Rocchiccioli P, Good R et al (2018) Systemic microvascular dysfunction in microvascular and vasospastic angina. Eur Heart J 39(46):4086–4097CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Camici PG, Tschope C, di Carli MF et al (2020) Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovasc Res 116(4):806–816CrossRefPubMed Camici PG, Tschope C, di Carli MF et al (2020) Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovasc Res 116(4):806–816CrossRefPubMed
12.
Zurück zum Zitat Petersen SE, Jerosch-Herold M, Hudsmith LE et al (2007) Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115(18):2418–2425CrossRefPubMed Petersen SE, Jerosch-Herold M, Hudsmith LE et al (2007) Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115(18):2418–2425CrossRefPubMed
13.
Zurück zum Zitat Miller RJH, Mikami Y, Heydari B et al (2020) Sex-specific relationships between patterns of ventricular remodelling and clinical outcomes. Eur Heart J Cardiovasc Imaging 21(9):983–990CrossRefPubMed Miller RJH, Mikami Y, Heydari B et al (2020) Sex-specific relationships between patterns of ventricular remodelling and clinical outcomes. Eur Heart J Cardiovasc Imaging 21(9):983–990CrossRefPubMed
14.
Zurück zum Zitat Huang BT, Peng Y, Liu W et al (2014) Subclassification of left ventricular hypertrophy based on dilation stratifies coronary artery disease patients with distinct risk. Eur J Clin Invest 44(10):893–901CrossRefPubMed Huang BT, Peng Y, Liu W et al (2014) Subclassification of left ventricular hypertrophy based on dilation stratifies coronary artery disease patients with distinct risk. Eur J Clin Invest 44(10):893–901CrossRefPubMed
15.
Zurück zum Zitat Murphy ML, Thenabadu PN, de Soyza N et al (1985) Sensitivity of electrocardiographic criteria for left ventricular hypertrophy according to type of cardiac disease. Am J Cardiol 55(5):545–549CrossRefPubMed Murphy ML, Thenabadu PN, de Soyza N et al (1985) Sensitivity of electrocardiographic criteria for left ventricular hypertrophy according to type of cardiac disease. Am J Cardiol 55(5):545–549CrossRefPubMed
16.
Zurück zum Zitat Grothues F, Smith GC, Moon JC et al (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90(1):29–34CrossRefPubMed Grothues F, Smith GC, Moon JC et al (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90(1):29–34CrossRefPubMed
17.
Zurück zum Zitat Lang RM, Bierig M, Devereux RB et al (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7(2):79–108CrossRefPubMed Lang RM, Bierig M, Devereux RB et al (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7(2):79–108CrossRefPubMed
18.
Zurück zum Zitat Kunadian V, Chieffo A, Camici PG et al (2021) An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. EuroIntervention 16(13):1049–1069CrossRefPubMedPubMedCentral Kunadian V, Chieffo A, Camici PG et al (2021) An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. EuroIntervention 16(13):1049–1069CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219CrossRefPubMed Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219CrossRefPubMed
20.
Zurück zum Zitat Najjar RS, Schwartz AM, Wong BJ et al (2021) Berries and their polyphenols as a potential therapy for coronary microvascular dysfunction: a mini-review. Int J Mol Sci 22(7):3373CrossRefPubMedPubMedCentral Najjar RS, Schwartz AM, Wong BJ et al (2021) Berries and their polyphenols as a potential therapy for coronary microvascular dysfunction: a mini-review. Int J Mol Sci 22(7):3373CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Selthofer-Relatic K, Bosnjak I, Kibel A (2016) Obesity related coronary microvascular dysfunction: from basic to clinical practice. Cardiol Res Pract 2016:8173816CrossRefPubMedPubMedCentral Selthofer-Relatic K, Bosnjak I, Kibel A (2016) Obesity related coronary microvascular dysfunction: from basic to clinical practice. Cardiol Res Pract 2016:8173816CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Tsujita K, Yamanaga K, Komura N et al (2015) Impact of left ventricular hypertrophy on impaired coronary microvascular dysfunction. Int J Cardiol 187:411–413CrossRefPubMed Tsujita K, Yamanaga K, Komura N et al (2015) Impact of left ventricular hypertrophy on impaired coronary microvascular dysfunction. Int J Cardiol 187:411–413CrossRefPubMed
23.
Zurück zum Zitat Kessler EL, Rivaud MR, Vos MA et al (2019) Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular disease. Biol Sex Differ 10(1):7CrossRefPubMedPubMedCentral Kessler EL, Rivaud MR, Vos MA et al (2019) Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular disease. Biol Sex Differ 10(1):7CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Dykun I, Karner L, Mahmoud I et al (2020) Association of echocardiographic measures of left ventricular diastolic dysfunction and hypertrophy with presence of coronary microvascular dysfunction. Int J Cardiol Heart Vasc 27:100493PubMedPubMedCentral Dykun I, Karner L, Mahmoud I et al (2020) Association of echocardiographic measures of left ventricular diastolic dysfunction and hypertrophy with presence of coronary microvascular dysfunction. Int J Cardiol Heart Vasc 27:100493PubMedPubMedCentral
25.
Zurück zum Zitat Reynolds HR, Diaz A, Cyr DD et al (2023) Ischemia with nonobstructive coronary arteries: insights from the ISCHEMIA trial. JACC Cardiovasc Imaging 16(1):63–74CrossRefPubMed Reynolds HR, Diaz A, Cyr DD et al (2023) Ischemia with nonobstructive coronary arteries: insights from the ISCHEMIA trial. JACC Cardiovasc Imaging 16(1):63–74CrossRefPubMed
26.
Zurück zum Zitat Verma A, Meris A, Skali H et al (2008) Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging 1(5):582–591CrossRefPubMed Verma A, Meris A, Skali H et al (2008) Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging 1(5):582–591CrossRefPubMed
27.
Zurück zum Zitat di Carli MF, Janisse J, Grunberger G et al (2003) Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 41(8):1387–1393CrossRefPubMed di Carli MF, Janisse J, Grunberger G et al (2003) Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 41(8):1387–1393CrossRefPubMed
28.
Zurück zum Zitat Ghosh AK, Hardy RJ, Francis DP et al (2014) Midlife blood pressure change and left ventricular mass and remodelling in older age in the 1946 British Birth Cohort Study. Eur Heart J 35(46):3287–3295CrossRefPubMedPubMedCentral Ghosh AK, Hardy RJ, Francis DP et al (2014) Midlife blood pressure change and left ventricular mass and remodelling in older age in the 1946 British Birth Cohort Study. Eur Heart J 35(46):3287–3295CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Urbina EM, Mendizabal B, Becker RC et al (2019) Association of blood pressure level with left ventricular mass in adolescents. Hypertension 74(3):590–596CrossRefPubMed Urbina EM, Mendizabal B, Becker RC et al (2019) Association of blood pressure level with left ventricular mass in adolescents. Hypertension 74(3):590–596CrossRefPubMed
30.
Zurück zum Zitat Leung DY, Leung M (2011) Non-invasive/invasive imaging: significance and assessment of coronary microvascular dysfunction. Heart 97(7):587–595CrossRefPubMed Leung DY, Leung M (2011) Non-invasive/invasive imaging: significance and assessment of coronary microvascular dysfunction. Heart 97(7):587–595CrossRefPubMed
31.
Zurück zum Zitat Michelsen MM, Pena A, Mygind ND et al (2016) Coronary flow velocity reserve assessed by transthoracic Doppler: the iPOWER study: factors influencing feasibility and quality. J Am Soc Echocardiogr 29(7):709–716CrossRefPubMed Michelsen MM, Pena A, Mygind ND et al (2016) Coronary flow velocity reserve assessed by transthoracic Doppler: the iPOWER study: factors influencing feasibility and quality. J Am Soc Echocardiogr 29(7):709–716CrossRefPubMed
32.
Zurück zum Zitat Knuuti J, Wijns W, Saraste A et al (2020) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41(3):407–477CrossRefPubMed Knuuti J, Wijns W, Saraste A et al (2020) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41(3):407–477CrossRefPubMed
33.
Zurück zum Zitat Rodriguez-Zanella H, Arbucci R, Fritche-Salazar JF et al (2022) Vasodilator strain stress echocardiography in suspected coronary microvascular angina. J Clin Med 11(3):711CrossRefPubMedPubMedCentral Rodriguez-Zanella H, Arbucci R, Fritche-Salazar JF et al (2022) Vasodilator strain stress echocardiography in suspected coronary microvascular angina. J Clin Med 11(3):711CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Liu TT, Ding MY, Sun DD et al (2021) Clinical value of TDI combined with 2D-STI on evaluating the microcirculation dysfunction and left ventricular dysfunction in patients with non-obstructive coronary angina. Zhonghua Xin Xue Guan Bing Za Zhi 49(12):1191–1197PubMed Liu TT, Ding MY, Sun DD et al (2021) Clinical value of TDI combined with 2D-STI on evaluating the microcirculation dysfunction and left ventricular dysfunction in patients with non-obstructive coronary angina. Zhonghua Xin Xue Guan Bing Za Zhi 49(12):1191–1197PubMed
35.
Zurück zum Zitat Xing X, Li D, Chen S et al (2020) Evaluation of left ventricular systolic function in patients with different types of ischemic heart disease by two-dimensional speckle tracking imaging. J Cardiothorac Surg 15(1):325CrossRefPubMedPubMedCentral Xing X, Li D, Chen S et al (2020) Evaluation of left ventricular systolic function in patients with different types of ischemic heart disease by two-dimensional speckle tracking imaging. J Cardiothorac Surg 15(1):325CrossRefPubMedPubMedCentral
Metadaten
Titel
The role of left ventricular hypertrophy measured by echocardiography in screening patients with ischaemia with non-obstructive coronary arteries: a cross-sectional study
verfasst von
Hao Yang
Hua Teng
Peng Luo
Ruqian Fu
Xiaoting Wang
Guang Qin
Min Gao
Jianli Ren
Publikationsdatum
26.05.2023
Verlag
Springer Netherlands
Erschienen in
The International Journal of Cardiovascular Imaging / Ausgabe 9/2023
Print ISSN: 1569-5794
Elektronische ISSN: 1875-8312
DOI
https://doi.org/10.1007/s10554-023-02879-x

Weitere Artikel der Ausgabe 9/2023

The International Journal of Cardiovascular Imaging 9/2023 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.